Raymond James cuts BridgeBio Oncology Thera price target to $22
Raymond James maintained a rating of Outperform on BridgeBio Oncology Thera and cut its price target to $22.00 from $24.00, according to Benzinga (TradingView News).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.